These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 34487739)

  • 21. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teprotumumab for the treatment of chronic thyroid eye disease.
    Ugradar S; Kang J; Kossler AL; Zimmerman E; Braun J; Harrison AR; Bose S; Cockerham K; Douglas RS
    Eye (Lond); 2022 Aug; 36(8):1553-1559. PubMed ID: 34244669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Therapeutic Approaches for Graves' Orbitopathy - are Targeted Therapies the Future?
    Eckstein A; Stöhr M; Görtz GE; Gulbins A; Möller L; Fuehrer-Sakel D; Oeverhaus M
    Klin Monbl Augenheilkd; 2024 Jan; 241(1):48-68. PubMed ID: 37799096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
    Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
    Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates on the understanding and management of thyroid eye disease.
    Men CJ; Kossler AL; Wester ST
    Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
    Singh G; Taylor B; Michalek S
    Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.
    Wang Y; Patel A; Douglas RS
    Ther Clin Risk Manag; 2019; 15():1305-1318. PubMed ID: 31814726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and Side Effects of Lateral Orbital Wall Decompression Including the Orbital Rim in Patients with Graves' Orbitopathy].
    Horn M; Schittkowski MP
    Klin Monbl Augenheilkd; 2019 Jan; 236(1):17-24. PubMed ID: 30690696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid eye disease: Redefining its management-A review.
    Jain AP; Jaru-Ampornpan P; Douglas RS
    Clin Exp Ophthalmol; 2021 Mar; 49(2):203-211. PubMed ID: 33484076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
    Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
    Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
    Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
    Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
    Girnita L; Smith TJ; Janssen JAMJL
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
    Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical challenge: An orbital Hickam's dictum.
    Wilson ME; Thornton S; Murchison AP; Bilyk JR
    Surv Ophthalmol; 2016; 61(6):799-805. PubMed ID: 26994869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.